D-0105-2025 Class II Ongoing

Recalled by Rising Pharma Holding, Inc. — East Brunswick, NJ

FDA drug recall D-0105-2025 was initiated by Rising Pharma Holding, Inc. on Nov 19, 2024 and is designated Class II. Reason for recall: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit The recall status is ongoing. Affected quantity: 209,376 bottles.

Recall details

Product Type
Drugs
Report Date
Dec 11, 2024
Initiation Date
Nov 19, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
209,376 bottles

Product description

Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ NDC 57237-017-60

Reason for recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit

Distribution pattern

Nationwide.

Code information

a) Lot # DT2022023A, DT2022024A, DT2022025A, DT2022026A, DT2022027A, exp. date Nov-24 DT2023001B, DT2023004A, DT2023005A, DT2023006A, exp. date Jan-25

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0105-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0105-2025. Report a data issue: hello@regdatalab.com.